{"transactions":[{"id":1156327,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant","published_at":"2025-05-07T21:48:30.000Z","date":"2025-05-02","kind":"other","planned":false,"acquired":false,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.5,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-25-045741","document":"tm2514380-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465925045741/tm2514380-2_4seq1.xml","form_type":"4"}},{"id":1156326,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2025-05-07T21:48:30.000Z","date":"2025-05-02","kind":"other","planned":false,"acquired":false,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.45,"exercise_date":"2023-12-13","expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-25-045741","document":"tm2514380-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465925045741/tm2514380-2_4seq1.xml","form_type":"4"}},{"id":1156325,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2025-05-07T21:48:30.000Z","date":"2025-05-02","kind":"purchase","planned":false,"acquired":true,"shares":1148482,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":2431763,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1148482},"source":{"system":"sec-edgar","filing":"0001104659-25-045741","document":"tm2514380-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465925045741/tm2514380-2_4seq1.xml","form_type":"4"}},{"id":1387667,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2024-10-11T18:12:54.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":574241,"derivative":{"exercise_price":0.45,"exercise_date":"2023-12-13","expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108139","document":"tm2425783-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924108139/tm2425783-2_4seq1.xml","form_type":"4"}},{"id":1387666,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2024-10-11T18:12:54.000Z","date":"2024-10-04","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.25,"exercise_date":"2023-12-13","expiration_date":"2025-06-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108139","document":"tm2425783-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924108139/tm2425783-2_4seq1.xml","form_type":"4"}},{"id":1387665,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrant","published_at":"2024-10-11T18:12:54.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":709040,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":709040,"derivative":{"exercise_price":0.27,"exercise_date":"2024-10-04","expiration_date":"2027-10-04","underlying":"Common Stock","underlying_shares":709040},"source":{"system":"sec-edgar","filing":"0001104659-24-108139","document":"tm2425783-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924108139/tm2425783-2_4seq1.xml","form_type":"4"}},{"id":1387664,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77988,"kind":"person","name":"Bios Clinical Opportunity Fund, LP","position":6,"cik":"0001988639","reported_name":"Bios Clinical Opportunity Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77987,"kind":"person","name":"Bios Equity COF, LP","position":7,"cik":"0002000747","reported_name":"Bios Equity COF, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":8,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":9,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2024-10-11T18:12:54.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":709040,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":1283281,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108139","document":"tm2425783-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2000747/000110465924108139/tm2425783-2_4seq1.xml","form_type":"4"}},{"id":1711733,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":6,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":7,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":8,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant","published_at":"2023-12-14T06:00:54.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF Fund. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF Fund. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors my be deemed to beneficially own the securities held directly by Bios COF Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":574241,"derivative":{"exercise_price":1.5,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-23-125826","document":"tm2332814-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923125826/tm2332814-1_4seq1.xml","form_type":"4"}},{"id":1711732,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":6,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":7,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":8,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2023-12-14T06:00:54.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF Fund. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF Fund. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors my be deemed to beneficially own the securities held directly by Bios COF Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":574241,"derivative":{"exercise_price":1.25,"exercise_date":"2023-12-13","expiration_date":"2025-06-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-23-125826","document":"tm2332814-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923125826/tm2332814-1_4seq1.xml","form_type":"4"}},{"id":1711731,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":6,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":7,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":8,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2023-12-14T06:00:54.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a Securities Purchase Agreement, dated as of December 11, 2023, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the other purchasers signatory thereto, Bios COF Fund purchased from the Issuer in a private placement 574,241 units at a price of $1.22 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock, (ii) one Series A warrant to purchase one share of Common Stock and (iii) one Series B warrant to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF Fund. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF Fund. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors my be deemed to beneficially own the securities held directly by Bios COF Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":574241,"derivative":{"exercise_price":0.0001,"exercise_date":"2023-12-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-23-125826","document":"tm2332814-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923125826/tm2332814-1_4seq1.xml","form_type":"4"}},{"id":2088986,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":6,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":7,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":8,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-13T07:00:41.000Z","date":"2022-12-12","kind":"purchase","acquired":true,"shares":8735,"price":2.4788,"value":21652.318,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.58, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are directly held by Bios Fund III."}],"balance_after":570724,"source":{"system":"sec-edgar","filing":"0001104659-22-126432","document":"tm2232534-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465922126432/tm2232534-1_4seq1.xml","form_type":"4"}},{"id":2088985,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":6,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":7,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":8,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-13T07:00:41.000Z","date":"2022-12-12","kind":"purchase","acquired":true,"shares":57052,"price":2.4788,"value":141420.4976,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.58, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are directly held by Bios Fund III QP."}],"balance_after":3727597,"source":{"system":"sec-edgar","filing":"0001104659-22-126432","document":"tm2232534-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465922126432/tm2232534-1_4seq1.xml","form_type":"4"}},{"id":2088984,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":6,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":7,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":8,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-13T07:00:41.000Z","date":"2022-12-12","kind":"purchase","acquired":true,"shares":9214,"price":2.4788,"value":22839.6632,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.58, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by Bios Fund III NT."}],"balance_after":601980,"source":{"system":"sec-edgar","filing":"0001104659-22-126432","document":"tm2232534-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465922126432/tm2232534-1_4seq1.xml","form_type":"4"}},{"id":2149669,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":6,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":7,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":8,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-29T06:14:47.000Z","date":"2022-09-28","kind":"purchase","acquired":true,"shares":2913,"price":2.0214,"value":5888.3382,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $2.15, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are directly held by Bios Fund III."}],"balance_after":561989,"source":{"system":"sec-edgar","filing":"0001104659-22-103860","document":"tm2226891-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465922103860/tm2226891-1_4seq1.xml","form_type":"4"}},{"id":2149668,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":6,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":7,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":8,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-29T06:14:47.000Z","date":"2022-09-28","kind":"purchase","acquired":true,"shares":19017,"price":2.0214,"value":38440.9638,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $2.15, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are directly held by Bios Fund III QP."}],"balance_after":3670545,"source":{"system":"sec-edgar","filing":"0001104659-22-103860","document":"tm2226891-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465922103860/tm2226891-1_4seq1.xml","form_type":"4"}},{"id":2149667,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":2,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":3,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":4,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":6,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":7,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":8,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-29T06:14:47.000Z","date":"2022-09-28","kind":"purchase","acquired":true,"shares":3070,"price":2.0214,"value":6205.698,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $2.15, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by Bios Fund III NT."}],"balance_after":592766,"source":{"system":"sec-edgar","filing":"0001104659-22-103860","document":"tm2226891-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465922103860/tm2226891-1_4seq1.xml","form_type":"4"}},{"id":2170837,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T13:16:09.000Z","date":"2022-08-29","kind":"purchase","acquired":true,"shares":4660,"price":2.02,"value":9413.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are directly held by Bios Fund III."}],"balance_after":559076,"source":{"system":"sec-edgar","filing":"0001104659-22-095951","document":"tm2224783-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095951/tm2224783-2_4seq1.xml","form_type":"4"}},{"id":2170836,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T13:16:09.000Z","date":"2022-08-26","kind":"purchase","acquired":true,"shares":1306,"price":2.01,"value":2625.06,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are directly held by Bios Fund III."}],"balance_after":554416,"source":{"system":"sec-edgar","filing":"0001104659-22-095951","document":"tm2224783-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095951/tm2224783-2_4seq1.xml","form_type":"4"}},{"id":2170835,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T13:16:09.000Z","date":"2022-08-29","kind":"purchase","acquired":true,"shares":30428,"price":2.02,"value":61464.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are directly held by Bios Fund III QP."}],"balance_after":3651528,"source":{"system":"sec-edgar","filing":"0001104659-22-095951","document":"tm2224783-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095951/tm2224783-2_4seq1.xml","form_type":"4"}},{"id":2170834,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T13:16:09.000Z","date":"2022-08-26","kind":"purchase","acquired":true,"shares":8531,"price":2.01,"value":17147.31,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are directly held by Bios Fund III QP."}],"balance_after":3621100,"source":{"system":"sec-edgar","filing":"0001104659-22-095951","document":"tm2224783-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095951/tm2224783-2_4seq1.xml","form_type":"4"}},{"id":2170833,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T13:16:09.000Z","date":"2022-08-29","kind":"purchase","acquired":true,"shares":4912,"price":2.02,"value":9922.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by Bios Fund III NT."}],"balance_after":589696,"source":{"system":"sec-edgar","filing":"0001104659-22-095951","document":"tm2224783-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095951/tm2224783-2_4seq1.xml","form_type":"4"}},{"id":2170832,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T13:16:09.000Z","date":"2022-08-26","kind":"purchase","acquired":true,"shares":1377,"price":2.01,"value":2767.77,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by Bios Fund III NT."}],"balance_after":584784,"source":{"system":"sec-edgar","filing":"0001104659-22-095951","document":"tm2224783-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095951/tm2224783-2_4seq1.xml","form_type":"4"}},{"id":2170831,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T08:10:20.000Z","date":"2022-08-29","kind":"purchase","acquired":true,"shares":4660,"price":2.02,"value":9413.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are directly held by Bios Fund III."}],"balance_after":559076,"source":{"system":"sec-edgar","filing":"0001104659-22-095839","document":"tm2224783-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095839/tm2224783-1_4seq1.xml","form_type":"4"}},{"id":2170830,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T08:10:20.000Z","date":"2022-08-26","kind":"purchase","acquired":true,"shares":1306,"price":2.01,"value":2625.06,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are directly held by Bios Fund III."}],"balance_after":554416,"source":{"system":"sec-edgar","filing":"0001104659-22-095839","document":"tm2224783-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095839/tm2224783-1_4seq1.xml","form_type":"4"}},{"id":2170829,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T08:10:20.000Z","date":"2022-08-29","kind":"purchase","acquired":true,"shares":30428,"price":2.02,"value":61464.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are directly held by Bios Fund III QP."}],"balance_after":3651528,"source":{"system":"sec-edgar","filing":"0001104659-22-095839","document":"tm2224783-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095839/tm2224783-1_4seq1.xml","form_type":"4"}},{"id":2170828,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T08:10:20.000Z","date":"2022-08-26","kind":"purchase","acquired":true,"shares":8531,"price":2.01,"value":17147.31,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are directly held by Bios Fund III QP."}],"balance_after":3621100,"source":{"system":"sec-edgar","filing":"0001104659-22-095839","document":"tm2224783-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095839/tm2224783-1_4seq1.xml","form_type":"4"}},{"id":2170827,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T08:10:20.000Z","date":"2022-08-29","kind":"purchase","acquired":true,"shares":4912,"price":2.02,"value":9922.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by Bios Fund III NT."}],"balance_after":589696,"source":{"system":"sec-edgar","filing":"0001104659-22-095839","document":"tm2224783-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095839/tm2224783-1_4seq1.xml","form_type":"4"}},{"id":2170826,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-30T08:10:20.000Z","date":"2022-08-26","kind":"purchase","acquired":true,"shares":1377,"price":2.01,"value":2767.77,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.97 to $2.08, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by Bios Fund III NT."}],"balance_after":584784,"source":{"system":"sec-edgar","filing":"0001104659-22-095839","document":"tm2224783-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922095839/tm2224783-1_4seq1.xml","form_type":"4"}},{"id":2179660,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-18T20:00:30.000Z","date":"2022-08-17","kind":"purchase","acquired":true,"shares":5823,"price":1.93,"value":11238.39,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $2.23, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are directly held by Bios Fund III."}],"balance_after":553110,"source":{"system":"sec-edgar","filing":"0001104659-22-092685","document":"tm2223668-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922092685/tm2223668-3_4seq1.xml","form_type":"4"}},{"id":2179659,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-18T20:00:30.000Z","date":"2022-08-17","kind":"purchase","acquired":true,"shares":38035,"price":1.93,"value":73407.55,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $2.23, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are directly held by Bios Fund III QP."}],"balance_after":3612569,"source":{"system":"sec-edgar","filing":"0001104659-22-092685","document":"tm2223668-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922092685/tm2223668-3_4seq1.xml","form_type":"4"}},{"id":2179658,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-18T20:00:30.000Z","date":"2022-08-17","kind":"purchase","acquired":true,"shares":6142,"price":1.93,"value":11854.06,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $2.23, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by Bios Fund III NT."}],"balance_after":583407,"source":{"system":"sec-edgar","filing":"0001104659-22-092685","document":"tm2223668-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465922092685/tm2223668-3_4seq1.xml","form_type":"4"}},{"id":2183054,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":4,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T10:27:37.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":206575,"price":1.9,"value":392492.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are directly held by Bios Fund III."}],"balance_after":540287,"source":{"system":"sec-edgar","filing":"0001104659-22-092057","document":"tm2223668-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1791916/000110465922092057/tm2223668-2_4seq1.xml","form_type":"4"}},{"id":2183053,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":4,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T10:27:37.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":1349218,"price":1.9,"value":2563514.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are directly held by Bios Fund III QP."}],"balance_after":3574534,"source":{"system":"sec-edgar","filing":"0001104659-22-092057","document":"tm2223668-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791916/000110465922092057/tm2223668-2_4seq1.xml","form_type":"4"}},{"id":2183052,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":4,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T10:27:37.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":217891,"price":1.9,"value":413992.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu Advisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by Bios Fund III NT."}],"balance_after":217891,"source":{"system":"sec-edgar","filing":"0001104659-22-092057","document":"tm2223668-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791916/000110465922092057/tm2223668-2_4seq1.xml","form_type":"4"}},{"id":2618016,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":false,"shares":326795,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities are directly held by Bios Fund III NT."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":359374},"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618015,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":false,"shares":2023568,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The securities are directly held by Bios Fund III QP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2225316},"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618014,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":false,"shares":309823,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities are directly held by Bios Fund III."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":340712},"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618013,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":false,"shares":907007,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities are directly held by BIOS Incysus."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":997433},"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618012,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":false,"shares":228438,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The securities are directly held by Bios Fund II NT."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":251211},"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618011,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":false,"shares":1706490,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are directly held by Bios Fund II QP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1876624},"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618010,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":false,"shares":522355,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Bios Fund II, LP (\"Bios Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":574432},"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618009,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":true,"shares":359374,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities are directly held by Bios Fund III NT."}],"balance_after":359374,"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618008,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":true,"shares":2225316,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The securities are directly held by Bios Fund III QP."}],"balance_after":2225316,"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618007,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":true,"shares":340712,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities are directly held by Bios Fund III."}],"balance_after":340712,"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618006,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":true,"shares":997433,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities are directly held by BIOS Incysus."}],"balance_after":997433,"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618005,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":true,"shares":251211,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The securities are directly held by Bios Fund II NT."}],"balance_after":251211,"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618004,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":true,"shares":1876624,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are directly held by Bios Fund II QP."}],"balance_after":1876624,"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}},{"id":2618003,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":2,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":3,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":4,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80067,"kind":"organization","name":"BIOS Incysus Co-Invest I, LP","position":5,"cik":"0001740029","reported_name":"BIOS Incysus Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":6,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":8,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":9,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T16:57:29.000Z","date":"2021-08-03","kind":"exercise","acquired":true,"shares":574432,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Bios Fund II, LP (\"Bios Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP (\"Bios Fund II\nQP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and BIOS Incysus Co-Invest I, LP (\"BIOS Incysus\"). Bios Equity Partners III, LP (\"Bios Equity III\")\nis the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III\nNT, LP (\"Bios Fund III NT\"). Bios Capital Management, LP (\"Bios Management\") and Cavu Management, LP (\"Cavu Management\") are the\ngeneral partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC (\"Bios Advisors\") is the general partner of Bios Management. Cavu\nAdvisors LLC (\"Cavu Advisors\") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and\ncontrolled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II,\nBios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the \"Bios Equity Entities\").\nBecause of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios\nManagement and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any\nsuch securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such\nReporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity\nEntities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu\nManagement and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."}],"balance_after":574432,"source":{"system":"sec-edgar","filing":"0001209191-21-049378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000120919121049378/doc4.xml","form_type":"4"}}]}